Insight Molecular Diagnostics Inc. — Director's Dealing 2021

Mar 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-03-19

Reporting Person: ANDREWS RONALD ASBURY (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-19	Common Stock, no par value	P	11000	$4.7911	Acquired	113698	Direct

Footnotes

F1: The shares were purchased at various prices ranging from $4.76 to $4.81.